Cover Image
市場調查報告書

Karo Bio AB:產品平台分析

Karo Bio AB - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 276016
出版日期 內容資訊 英文 26 Pages
訂單完成後即時交付
價格
Back to Top
Karo Bio AB:產品平台分析 Karo Bio AB - Product Pipeline Review - 2015
出版日期: 2015年07月15日 內容資訊: 英文 26 Pages
簡介

Karo Bio AB是著重於醫藥品開發與創新的製藥企業。核受體是該公司主要的研究範圍。

本報告提供Karo Bio AB的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Karo Bio AB的基本資料

  • Karo Bio AB概要
  • 主要資訊
  • 企業資料

Karo Bio AB:R&D概要

  • 主要的治療範圍

Karo Bio AB:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Karo Bio AB:開發中產品概況

  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Karo Bio AB:藥物簡介

  • KB-3944
  • KB-9520
  • 以糖皮質素受體為目標的發炎醫藥品
  • Nur-77受體為目標的自體免疫疾病醫藥品
  • NURR-1受體為目標的自體免疫疾病醫藥品
  • ROR伽馬為目標的自體免疫疾病醫藥品

Karo Bio AB:開發平台分析

  • 標的別
  • 各分子類型
  • 各作用機制

Karo Bio AB:最近的開發平台趨勢

Karo Bio AB:暫停中的計劃

Karo Bio AB:中止發的開發中產品

  • 中止發的開發中產品簡介
    • eprotirome
    • KB-002611
    • KB-5359

Karo Bio AB:企業發表

Karo Bio AB:總公司和子公司的所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07313CDB

Summary

Global Markets Direct's, 'Karo Bio AB - Product Pipeline Review - 2015', provides an overview of the Karo Bio AB's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Karo Bio AB's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Karo Bio AB including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Karo Bio AB's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Karo Bio AB's pipeline products

Reasons to buy

  • Evaluate Karo Bio AB's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Karo Bio AB in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Karo Bio AB's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Karo Bio AB and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Karo Bio AB
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Karo Bio AB and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Karo Bio AB Snapshot
    • Karo Bio AB Overview
    • Key Information
    • Key Facts
  • Karo Bio AB - Research and Development Overview
    • Key Therapeutic Areas
  • Karo Bio AB - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Karo Bio AB - Pipeline Products Glance
    • Karo Bio AB - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Karo Bio AB - Drug Profiles
    • KB-3944
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KB-9520
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Agonize Glucocorticoid Receptor for Inflammation
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Target Nur-77 Receptor for Autoimmune Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Agonize NURR1 for Autoimmune Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Antagonize ROR-Gamma for Autoimmune Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Karo Bio AB - Pipeline Analysis
    • Karo Bio AB - Pipeline Products by Target
    • Karo Bio AB - Pipeline Products by Molecule Type
    • Karo Bio AB - Pipeline Products by Mechanism of Action
  • Karo Bio AB - Recent Pipeline Updates
  • Karo Bio AB - Locations And Subsidiaries
  • Karo Bio AB - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Karo Bio AB, Key Information
  • Karo Bio AB, Key Facts
  • Karo Bio AB - Pipeline by Indication, 2015
  • Karo Bio AB - Pipeline by Stage of Development, 2015
  • Karo Bio AB - Monotherapy Products in Pipeline, 2015
  • Karo Bio AB - Out-Licensed Products in Pipeline, 2015
  • Karo Bio AB - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Karo Bio AB - Preclinical, 2015
  • Karo Bio AB - Discovery, 2015
  • Karo Bio AB - Pipeline by Target, 2015
  • Karo Bio AB - Pipeline by Molecule Type, 2015
  • Karo Bio AB - Pipeline Products by Mechanism of Action, 2015
  • Karo Bio AB - Recent Pipeline Updates, 2015
  • Karo Bio AB, Subsidiaries

List of Figures

  • Karo Bio AB - Pipeline by Top 10 Indication, 2015
  • Karo Bio AB - Pipeline by Stage of Development, 2015
  • Karo Bio AB - Monotherapy Products in Pipeline, 2015
  • Karo Bio AB - Pipeline by Top 10 Target, 2015
  • Karo Bio AB - Pipeline by Top 10 Molecule Type, 2015
  • Karo Bio AB - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top